Future studies will have to investigate whether inhibition of SCD could synergize with an ACE inhibitor or AT1 receptor antagonist to prevent detrimental and heart-failure-enhancing activities of SCD in patients with SCD-mediated pathologies. Here, AGTR1 is linked to heart failure.